California Healthcare Institute Launches Final Podcast Episode on Dangers of a Cost-based U.S. Healthcare System.Podcast Urges Lawmakers to Choose Care over Cost in Healthcare Proposals LA JOLLA La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , Calif. -- The California Healthcare Institute (CHI) today launched the final episode of the podcast series, Cost Over Care: The Dangers of Bureaucratic Medicine. As state and federal legislators design their healthcare proposals, this podcast aims to educate policymakers about the dangers of cost-based healthcare initiatives. The five-part podcast series can be found on the California Healthcare Institute Web site, www.chi.org, and is accessible on iTunes and other podcast directories. In the fifth and final episode, Dr. David Gollaher, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of CHI, urges state and federal policymakers to factor in individual patient differences, physician decision-making, and the need to provide incentives for future medical innovation into their healthcare proposals. "Access to healthcare remains a central concern for many Americans," said Gollaher. "As healthcare stakeholders Stakeholders All parties that have an interest, financial or otherwise, in a firm-stockholders, creditors, bondholders, employees, customers, management, the community, and the government. , policymakers and advocates we have a responsibility to find practical solutions to the problems of cost and affordable coverage. We cannot afford to compromise quality of care to balance our budgets." Previous podcast episodes feature Dr. Kwabena Adubofour, medical director, East Main Clinic and Stockton Diabetes Intervention Center; Meryl Comer, Emmy-award winning journalist and caregiver; and Peter J. Pitts, co-founder and president of the Center for Medicines in the Public Interest and former FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. associate commissioner for external relations. For more information about evidence-based medicine evidence-based medicine Decision-making 'The use of scientific data to confirm that proposed diagnostic or therapeutic procedures are appropriate in light of their high probability of producing the best and most favorable outcome'. See Meta-analysis. and cost-effectiveness analysis cost-effectiveness analysis Cost-utility analysis Clinical trials A form of economic analysis in which alternative interventions are compared in terms of the cost per unit of clinical effect–eg cost per life saved, per mm Hg of lowered BP, per yr of or to download podcast episodes, please visit the CHI Web site at www.chi.org. This series has been made possible through a grant from Pfizer Inc. California Healthcare Institute (CHI) represents more than 250 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research Biomedical research (or experimental medicine), in general simply known as medical research, is the basic research or applied research conducted to aid the body of knowledge in the field of medicine. organizations. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI's web site is http://www.chi.org. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion